Recent Updates
Recently added Catalysts
VYGR Positive Sentiment

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Monday, July 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Voyager Therapeutics presented data on VY1706, showing it was well tolerated in a six-month GLP toxicology study. The study demonstrated a reduction in tau levels, which is significant for Alzheimer's disease research. The company plans to initiate a clinical trial for VY1706 in Alzheimer's disease by the second half of 2026.
Price reaction · baseline $3.44 (2026-07-10 close) · hit pre-market · clean, no other VYGR news in the window
day 0 close
-5.8%
day 1
-8.1%
day 3 · peak
-11.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Single IV dose of VY1706 was well tolerated.
  • Demonstrated reduction of tau in the study.
  • Initiation of clinical trial in Alzheimer's expected in H2 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
3%
average across 2 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
VP4896
Phase 3 · Alzheimer's Disease

Full Press Release Details

- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice

Frequently Asked Questions

What is VY1706?

VY1706 is a therapeutic candidate developed by Voyager Therapeutics aimed at treating neurological diseases.

What were the results of the GLP study?

The GLP study showed that a single IV dose of VY1706 was well tolerated and reduced tau levels.

When is the clinical trial for VY1706 expected to start?

The clinical trial for VY1706 in Alzheimer's disease is expected to begin in the second half of 2026.

Where was the data on VY1706 presented?

The data was presented at the AAIC 2026 as a Developing Topics poster.

ShareAdd on Google
Tags: VYGR Viatris Investor Conferences Healthcare VY1706 Alzheimer's disease clinical trial toxicology study
Last updated: Jul 13, 2026

Biotech snapshot

Cash runway
$149M liquidity · $9M/mo burn
~17 mo
Low dilution risk
Lead asset
VP4896Phase 3
Alzheimer's Disease →

Catalyst track record

+14%
best trade around VYGR's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for VYGR.

See every catalyst's timing & PoA →